Wanbury Q1 FY26: 1,197% Profit Surge – From ICU to ICU (Intensely Cash-Utilized)

At a Glance

Wanbury Ltd just pulled a classic Bollywood comeback – from years of balance sheet ICU, it suddenly posted a whopping 1,197% YoY profit jump in Q1 FY26. Yes, from single digits to double digits – and analysts are still checking their calculators. The stock is up, the pledges are high (76.7% promoter shares locked), and the drama is sizzling. API exports are the star, domestic formulations are supporting actors, and the board is handing out ESOPs like candy. With a ROE of 70% and debt still lurking, Wanbury is the phoenix that rises – but only after borrowing fuel from the fire.

Introduction

When you think of pharma, you think of stability, R&D, and maybe a few patent disputes. Wanbury, on the other hand, prefers the rollercoaster.

Founded in 1988, this API (Active Pharmaceutical Ingredient) and formulations player has had a history of debt headaches, profit mood swings, and a promoter pledge ratio that screams “margin call incoming.” Despite that, it has quietly built a strong global API presence in 50+ countries and is leveraging domestic branded formulations to stabilize earnings.

The Q1 FY26 numbers have put this underdog back in the spotlight – profit soared 1,197% YoY, operating margins hit 15%, and the stock rallied 27% over the past year. But before you pop the champagne, remember: Wanbury’s debt, high cost of borrowing, and pledged shares are like those in-laws who always show up uninvited – they don’t go away easily.

Business Model (WTF Do They Even Do?)

Wanbury operates in two main segments:

1. APIs (Active Pharmaceutical Ingredients) – The company’s bread and butter, with exports to over 50 countries. These APIs are used by other pharma giants to manufacture final drugs. Think of Wanbury as the raw material supplier to the big boys.
2. Formulations – Domestic branded medicines that give it some retail muscle. It’s not Cipla-level big, but it’s enough to keep the cash registers ringing.

The business model is straightforward: make APIs, sell to global players, manufacture formulations for the domestic market, and repeat. Sounds simple? Add regulatory hurdles, price controls, and debt servicing, and suddenly it’s a juggling act.

The recent closure of three inactive subsidiaries hints at a leaner approach, and ESOP grants signal management confidence (or maybe just a morale booster). Either way, Wanbury is clearly trying to clean up its act.

Financials Overview

For Q1 FY26:

• Revenue: ₹163 Cr (YoY +24%)
• EBITDA: ₹24 Cr (YoY +70%)
• PAT: ₹13 Cr (YoY +1,197%)
• EPS: ₹4.10 (vs ₹0.32 YoY)

Margins: OPM stood at 15% and PAT margin at 8%. The jump in net profit is thanks to